The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Employer Drug Benefit Plans and Spending on Prescription Drugs
Abstract
CONTEXT: With drug spending rising rapidly for working-aged adults, many employers and health insurance providers have changed benefits packages to encourage use of fewer or less expensive drugs. It is unknown how these initiatives affect drug costs. OBJECTIVE: To examine how innovations in benefits packages, such as those that include multitier formularies and mandatory generic substitution, affect total cost to insurance providers for generic and brand drugs and out-of-pocket payments to beneficiaries. DESIGN AND PARTICIPANTS: Retrospective study from 1997 to 1999 linking claims data of 420,786 primary beneficiaries aged 18 through 64 years who worked at large firms (n = 25) with health insurance benefits that included outpatient drugs. MAIN OUTCOME MEASURES: Overall drug costs; generic, single-source brand, and multisource brand costs; and drug expenditures by health insurance providers and out-of-pocket costs for beneficiaries. RESULTS: For a 1-tier plan with a 5 US dollars co-payment for all drugs, the average annual spending was 725 US dollars per member. Doubling co-payments to 10 US dollars for all drugs reduced the annual average drug cost from 725 US dollars to 563 US dollars per member (22.3%, P<.001). Doubling co-payments in a 2-tier plan from 5 US dollars for generics and $10 for brand drugs to 10 US dollars for generics and 20 US dollars for brand drugs reduced costs from 678 US dollars to 455 US dollars (32.9%, P<.001). Adding an additional co-payment of 30 US dollars for nonpreferred brand drugs to a 2-tier plan (10 US dollars generics; 20 US dollars brand) lowered overall drug spending by 4% (P<.001). Requiring mandatory generic substitution in a 2-tier plan reduced drug spending by 8% (P<.001). Doubling co-payments in a 2-tier plan increased the fraction beneficiaries' paid out-of-pocket from 17.6% to 25.6%. CONCLUSIONS: Adding an additional level of co-payment, increasing existing co-payments or coinsurance rates, and requiring mandatory generic substitution all reduced plan payments and overall drug spending among working-age enrollees with employer-provided drug coverage. The reduction in drug spending largely benefited health insurance plans because the percentage of drug expenses beneficiaries paid out-of-pocket rose significantly.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schulz (1995) · doi:10.1001/jama.1995.03520290060030 · Cited by 5,634
Moher, D., Pham, B., Jones, A., Cook, D. J., Jadad, A. R., Moher, M., Tugwell, P., & Klassen, T. P. (1998) · The Lancet · doi:10.1016/s0140-6736(98)01085-x · Cited by 3,560
Assessing the quality of controlled clinical trials
Jüni, P., Altman, D. G., & Egger, M. (2001) · BMJ · doi:10.1136/bmj.323.7303.42 · Cited by 3,309
Systematic Review: Why sources of heterogeneity in meta-analysis should be investigated
Thompson, S. G. (1994) · BMJ · doi:10.1136/bmj.309.6965.1351 · Cited by 1,017
Cited by
Goldman, D. P., Joyce, G. F., & Zheng, Y. (2007) · JAMA · doi:10.1001/jama.298.1.61 · Cited by 874
Self-citationPharmacy Benefits and the Use of Drugs by the Chronically Ill
Goldman, D. P. (2004) · JAMA · doi:10.1001/jama.291.19.2344 · Cited by 530
Unintended Consequences of Caps on Medicare Drug Benefits
Hsu, J., Price, M., Huang, J., Brand, R., Fung, V., Hui, R., Fireman, B., Newhouse, J. P., & Selby, J. V. (2006) · New England Journal of Medicine · doi:10.1056/nejmsa054436 · Cited by 371
Shrank, W. H., Hoang, T., Ettner, S. L., Glassman, P. A., Nair, K., DeLapp, D., Dirstine, J., Avorn, J., & Asch, S. M. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.3.332 · Cited by 343
Building resilient health systems: a proposal for a resilience index
Kruk, M. E., Ling, E. J., Bitton, A., Cammett, M., Cavanaugh, K., Chopra, M., el-Jardali, F., Macauley, R. J., Muraguri, M. K., Konuma, S., et al. (2017) · BMJ · doi:10.1136/bmj.j2323 · Cited by 341
Metadata
- Authors
- Joyce, G. F.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2002-10-09
- Volume
- 288
- Issue
- 14
- Pages
- 1733
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2019502737
- Cited by
- 228
- References
- 4
- FWCI
- 51.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Employer Drug Benefit Plans and Spending on Prescription Drugs. https://app.cochat.ai/papers/10.1001/jama.288.14.1733
- The paper
- Joyce, G. F. (2002). Employer Drug Benefit Plans and Spending on Prescription Drugs. JAMA. https://doi.org/10.1001/jama.288.14.1733
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.